MYH14

Across TCGA pan-cancer cohorts, MYH14 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MYH14 data layer compared with 27 for mass-spec protein and 11 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher MYH14 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated MYH14 expression acts as an unfavorable survival marker, although some lineages such as PDAC and COAD show a favorable association.

PDAC, COAD, and CCRCC are the cancer types where MYH14 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	III,IV	0.682	0.323	.002	40	view →
COAD	DFS	Median	All	1.000	0.887	.020	30	view →
CCRCC	DFS	Median	II,III,IV	0.295	0.827	.010	4	view →
HNSC	DFS	Median	All	0.987	0.917	.043	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

MYH14–PDAC (OS)

Open the PDAC breakdown →